Clinical trials: Tamoxifen
Endometrial Hyperplasia, Osteoporosis
Study Evaluating Safety and Efficacy of Bazedoxifene/Conjugated Estrogens Combinations in Postmenopausal Women
The purpose of this study is to determine whether bazedoxifene/conjugated estrogens combinations are effective for the prevention of endometrial hyperplasia and for the prevention of osteoporosis in postmenopausal women.
- Trial name
- NCT00675688
- Testing
- Bazedoxifene/Conjugate Estrogens (CE), Raloxifene
- Volunteers
- 3,544 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Advanced Cancer
A Study of LY2228820 in Participants With Advanced Cancer
The objective of this study is to determine a safe dose of LY2228820 that may be given to participants with advanced cancer. Part A of this study will consist of dose escalation, and Part B will consist of dose confirmation.
- Trial name
- NCT01393990
- Testing
- LY2228820, Midazolam, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Premenopausal Endocrine Responsive Chemotherapy Trial
The PERCHE trial evaluated the worth of adding adjuvant chemotherapy for premenopausal women with steroid hormone receptor positive early invasive breast cancer who receive ovarian function suppression plus either tamoxifen or…
- Trial name
- PERCHE (NCT00066807)
- Testing
- chemotherapy, exemestane, tamoxifen
- Where
- 6 sites in Hungary, Italy and 1 more
- Volunteers
- 29 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer
Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients With Hormone Receptor-Positive HER2-negative Breast Cancer
This is an exploratory phase II interventional study that initiates standard-of-care anti-estrogen treatment preoperatively for 4-12 weeks (+/- 2 weeks).
- Trial name
- MAPPER (NCT06361940)
- Testing
- Aromatase inhibitors or tamoxifen
- Where
- United States
- Volunteers
- 185 people
- Sponsor
- Medical College of Wisconsin
Breast Cancer, Adjuvant Therapy
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
This study is a prospective, open-label, multicenter, randomized controlled Phase III clinical trial. Building upon anti-HER2 targeted therapy combined with endocrine therapy, the addition of CDK4/6 inhibitors has demonstrated…
- Trial name
- NCT07019363
- Testing
- Endocrine Therapy (Tamoxifen, Anastrozol, Letrozole, Exemestane), Standard endocrine therapy combined with CDK4/6 Inhibitor
- Where
- China
- Volunteers
- 1,903 people
- Sponsor
- Fudan University
Breast Cancer
Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.
The purpose of this study is to microscopically examine breast cancer cells of pre-menopausal and post-menopausal women before and after exposure to one of the two commonly used breast cancer drugs, tamoxifen or fulvestrant.
- Trial name
- NCT02936206
- Testing
- Fulvestrant, Tamoxifen
- Where
- 3 sites in United States
- Volunteers
- 2 people
- Sponsor
- Icahn School of Medicine at Mount Sinai
Breast Cancer Invasive
Density Lowering Effect of "OFS Add on to TMX"(DELFINO Trial)
DELFINO tial is designed to investigate the role of "OFS add on to TMX ", based on MMG density as a surrogate marker in premenopausal women Premise - MMG density as a surrogate marker of hormone therapy Assumption - "Add on OFS…
- Trial name
- NCT03664895
- Testing
- Leuplin or zoladex
- Where
- South Korea
- Volunteers
- 224 people
- Sponsor
- Seoul National University Hospital
Breast Cancer
Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Aromatase inhibitors, such as letrozole, anastrozole, and exemestane, may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- MNEMOSYNE (NCT00893061)
- Testing
- anastrozole, exemestane, letrozole
- Where
- 3 sites in France
- Volunteers
- 44 people
- Sponsor
- Centre Oscar Lambret
Breast Neoplasms, Neoplasms, Hormone-Dependent
The CAT Study: Atamestane Plus Toremifene Versus Letrozole in Advanced Breast Cancer
The purpose of this study is to determine whether maximal estrogen suppression achieved via the combination of an experimental drug, atamestane, plus an FDA-approved drug, toremifene (Fareston®), is more effective than another…
- Trial name
- NCT00097344
- Testing
- Atamestane, Toremifene, Letrozole
- Where
- 104 sites in United States, Bulgaria and 3 more
- Volunteers
- 842 people
- Sponsor
- Intarcia Therapeutics
Breast Cancer
Optimizing Extended Adjuvant Endocrine Therapy in Patients With Breast Cancer
Based on the risk of late recurrence in breast cancer patients with luminal disease with high-risk for recurrence, extended adjuvant endocrine therapy beyond 5 years is recommended as a valid treatment option.
- Trial name
- SWE-Switch (NCT06223698)
- Testing
- Letrozole, Anastrozole, Exemestane
- Where
- 15 sites in Sweden
- Volunteers
- 3,832 people
- Sponsor
- Region Örebro County
Breast Cancer
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
This is a prospective, randomized, open-label phase III clinical study on the efficacy and safety of fluzoparib combined with adjuvant endocrine therapy versus adjuvant endocrine therapy for HR+/HER2- SNF3-subtype early breast…
- Trial name
- NCT05891093
- Testing
- Fluzoparib, Anastrozole, Letrozole
- Where
- 15 sites in China
- Volunteers
- 766 people
- Sponsor
- Fudan University
Breast Atypical Hyperplasia, Breast Carcinoma
Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction
This phase II trial evaluates tamoxifen, with or without omega-3 fatty acids, for reducing risk of breast cancer among postmenopausal and overweight or obese women who are at increased risk of developing breast cancer.
- Conditions
- Breast Atypical Hyperplasia, Breast Carcinoma, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ
- Trial name
- NCT06195306
- Testing
- Biospecimen Collection, Mammography, Omega-3-Acid Ethyl Esters
- Where
- 3 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Lapatinib and Tamoxifen in Treating Patients With Advanced or Metastatic Breast Cancer
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Estrogen can cause the growth of breast cancer cells.
- Trial name
- LAPATAM (NCT00424164)
- Testing
- lapatinib ditosylate, tamoxifen citrate, pharmacological study
- Where
- France
- Volunteers
- 20 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Neoadjuvant Treatment of Breast Cancer
Observational investigation of participants who are given neoadjuvant treatment for invasive breast cancer. The scope of the study is to collect information on standardized treatment results, to explore the causes of dose…
- Trial name
- NCT05131893
- Testing
- Tamoxifen, Goserelin, Letrozole 2.5Mg Tab
- Where
- Hungary
- Volunteers
- 300 people
- Sponsor
- National Institute of Oncology, Hungary
Breast Cancer, Endometrial Hyperplasia and Endometrial Cancers
Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen
The goal of this clinical trial is to learn if metformin can reduce the increase in endometrial thickness caused by tamoxifen in women with estrogen-positive breast cancer taking tamoxifen for more than 1 year.
- Trial name
- NCT07145827
- Testing
- Metfomin, tamoxifen
- Where
- Iraq
- Volunteers
- 60 people
- Sponsor
- Uruk University
HR+ HER2- Men, Pre/Postmenopausal Advanced Breast Cancer
Treatment of Canadian Men and Pre/Peri/Post-menopausal Women With ER+ Advanced Breast Cancer in the Real-World Setting With Hormone Therapy ± Targeted Therapy
Although randomized controlled trials (RCTs) provide evidence of efficacy, generalization of these results to patients in the real-world setting is challenging, given RCTs are conducted in highly selected patient populations.
- Trial name
- Treat ER+ight (NCT02753686)
- Testing
- Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy
- Where
- 25 sites in Canada
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Schizophrenia, Schizoaffective Disorder
Raloxifene Augmentation in Patients With a Schizophrenia Spectrum Disorder
There is increasing clinical and molecular evidence for the role of hormones and specifically estrogen and its receptor in schizophrenia.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychosis NOS
- Trial name
- RAPSODI (NCT03043820)
- Testing
- Raloxifene
- Where
- Netherlands
- Volunteers
- 110 people
- Sponsor
- Iris Sommer
Endometrial Cancer, Cervical Cancer
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human…
- Conditions
- Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia
- Trial name
- ECHO (NCT05051722)
- Testing
- Vaginal Fluid Collection, Blood Collection
- Where
- 25 sites in United States
- Volunteers
- 3,110 people
- Sponsor
- Mayo Clinic
Breast Cancer, Adjuvant Drug Therapy
The POWER Trial: Personalised Dose Optimisation With Adjuvant Tamoxifen Therapy in Breast cancER
In Sweden, approximately 7000 women are diagnosed with hormone-sensitive breast cancer annually. According to international and national guidelines, most of these women are recommended anti-hormonal therapy for five to ten years…
- Trial name
- POWER (NCT07502820)
- Testing
- Individual dose of tamoxifen, Standard adjuvant therapy of tamoxifen
- Where
- 4 sites in Sweden
- Volunteers
- 1,100 people
- Sponsor
- Karolinska Institutet
Breast Neoplasms
Exemestane As Treatment In Adjuvant For Post-Menopausal Patients With Non-Metastatic Breast Cancer
To compare recurrence free survival between two treatment groups (5 years with exemestane vs 2.5 to 3 years tamoxifen followed by 2 to 2.5 years of exemestane for a total duration of 5 years) This Pfizer sponsored trial is part…
- Trial name
- TEAM (NCT00279448)
- Testing
- exemestane, tamoxifen
- Where
- 59 sites in France
- Volunteers
- 9,779 people
- Sponsor
- Pfizer